Sign in
CompletedPhase 3

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Key facts

Who runs it
Kowa Research Institute, Inc.
Where
Albuquerque, Ann Arbor, Blue Ash, Cleveland, Dallas, Fort Myers, Grand Rapids, Houston, Lexington, Los Angeles, Madison, New York, Omaha, Palm Beach Gardens, Palo Alto, Portland, Sacramento, San Antonio, West Fargo, and Wichita, United StatesSee the 21 sitesAlso in 5 other countries, 22 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
110 people enrolled
Started
11 May 2023
Ended
24 Oct 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ripasudil
  • Placebo
Record updated
22 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Is at least 18 years old at the screening visit (Visit 1)
  • Has a diagnosis of FECD at Visit 1
  • Meet all other inclusion criteria outlined in the Clinical Study Protocol

Who cannot take part

  • Is a female subject of childbearing potential and any of the following is true:; is pregnant or lactating/breastfeeding, or; is not surgically sterile, not post-menopausal (no menses for the previous 12 months), or not practicing an effective method of birth control as determined by the Investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy)
  • Meet any other exclusion criteria outlined in the Clinical Study Protocol

Where in United States

Also in 5 other countries, 22 sites

  • Eye Associates of New Mexico - Albuquerque - NorthsideAlbuquerque, United States
  • W Kellogg Eye CenterAnn Arbor, United States
  • Cincinnati Eye Institute-1945 Cei DrBlue Ash, United States
  • University Hospitals Cleveland Medical Center - 11100 Euclid AveCleveland, United States
  • University of Texas Southwestern Medical CenterDallas, United States
  • Gorovoy MD Eye SpecialistsFort Myers, United States
  • Verdier Eye CenterGrand Rapids, United States
  • Houston Eye AssociatesHouston, United States
  • University of KentuckyLexington, United States
  • Keck Hospital of USCLos Angeles, United States
  • Macy Eye CenterLos Angeles, United States
  • University of Wisconsin School of Medicine and Public HealthMadison, United States
  • NYU Langone HealthNew York, United States
  • Vance Thompson Vision - OmahaOmaha, United States
  • Bascom Palmer Eye InstitutePalm Beach Gardens, United States
  • Byers Eye Institute at StanfordPalo Alto, United States
  • Devers Eye InstitutePortland, United States
  • Sacramento Eye ConsultantsSacramento, United States
  • R and R Eye Research, LLCSan Antonio, United States
  • Vance Thompson Vision West FargoWest Fargo, United States
  • Grene Vision Group-WichitaWichita, United States

About the trial

What the trial wants to find out

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

The 2 groups in the trial

  • K-321Treatment being tested

    K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase

    Treatment: Ripasudil

  • PlaceboPlacebo, for comparison

    Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
Record updated
22 January 2026